12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 825 participants.

Also called NCT01370005

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 825 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01370005
  • EudraCT 2011-000347-25
Other papers using this trial's data
  • Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension Diabetes care, 2015-03 DOI, PubMed 25271206
  • Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive Medication Hypertension (Dallas, Tex. : 1979), 2016-12 DOI, PubMed 27977392

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Czechia, Denmark, Estonia, Finland, France, Germany, Lebanon, Netherlands, Norway, Sweden (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01370005. Randomized; double masking; primary purpose treatment. Start 2011-06 (registry gives no type); primary completion 2012-07 (actual). Results posted on 2014-06-17.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus
Condition
Diabetes Mellitus, Type 2
Condition
Hypertension
Intervention (Drug)
Placebo
Intervention (Drug)
BI 10773
Intervention (Drug)
Placebo
Intervention (Drug)
BI 10773
Intervention (Drug)
Placebo
Intervention (Drug)
Placebo
Lead sponsor
Boehringer Ingelheim (class: industry)
Collaborator
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01370005
Content hash
b429e7ff7038a7d7eb0579ecd8edd82b3585a772bfc6f2712c402225d84ab491